Navigation Links
Amyris Biotechnologies Announces $70 Million Series B Round

Prominent Investors Include DAG Ventures, Khosla Ventures, Kleiner Perkins

Caufield & Byers, and TPG Ventures Strong Endorsement of Technology Pioneer at Forefront of Developing No-

Compromise Biofuels

EMERYVILLE, Calif., Sept. 19 /PRNewswire/ -- Amyris Biotechnologies, an innovator in the development of renewable hydrocarbon biofuels, today announced that it closed the first tranche of its $70 million Series B funding. Duff Ackerman & Goodrich Ventures (DAG Ventures) led the financing and was joined by existing Series A investors, including Khosla Ventures, Kleiner Perkins Caufield & Byers, and TPG Ventures. The Series B funding will be used to further the development and scale up of its technology for the production of three transportation biofuels: bio-gasoline, bio-diesel, and bio-jet, and to support business initiatives to enable Amyris to bring its biofuels to market as early as 2010.

"Amyris has not only a break-through technology but a clearly defined strategy to commercialize a promising slate of next-generation biofuels that could have a profound impact on the transportation market," said R. Thomas Goodrich at DAG Ventures. "We are investing with strong confidence in what Amyris is creating as well as the management and scientific team the company is putting in place to execute on its vision."

"No-compromise transportation fuels derived from renewable sources hold substantial promise for meeting the tremendous need for alternative energy sources in the future," said John Melo, CEO of Amyris. "We have already succeeded in creating these biofuels in our lab. We are delighted with the strong interest in our Series B funding which will enable us to continue the research and scale-up of our technology and to implement our business model as the first biofuels company to go from production to customer."

Amyris pioneered a unique technology platform that allows it to use a variety of environmentally-friendly renewable feedstocks including sugarcane, corn and cellulose, to produce high-value compounds. This technology has been proven in Amyris' earlier non-profit project, funded through a grant to the Institute for One World Health from the Bill and Melinda Gates Foundation, to reduce the production cost of artemisinin-based anti-malarial drugs. Using the same technology platform, Amyris is now developing capabilities to produce a slate of high-performing hydrocarbon transportation biofuels that are environmentally friendly, cost- effective, and compatible with current engines and distribution infrastructure.

"Amyris is designing better biofuels from designer bugs," said John Doerr, partner at Kleiner Perkins Caufield & Byers. "This is a big deal because Amyris' cost competitive biofuels will work with existing engines without compromising performance and will have a lower carbon footprint. This financing will help Amyris scale with speed."

Amyris expects to close the second tranche of its Series B financing by the end of 2007.

About Amyris Biotechnologies

Amyris Biotechnologies ( is applying its proprietary, breakthrough technology to address major global health and energy challenges. Amyris' technology is used to produce high-value compounds to enable the production of lower cost artemisinin-based anti-malarial drugs and a slate of renewable hydrocarbon biofuels which are expected to be cost-effective and compatible with existing engines and distribution infrastructure. Based in Emeryville, CA, Amyris is a privately-held venture backed company whose investors include DAG Ventures, Khosla Ventures, Kleiner Perkins Caufield & Byers and TPG Ventures.

SOURCE Amyris Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):